home / stock / coll / coll news


COLL News and Press, Collegium Pharmaceutical Inc. From 05/19/22

Stock Information

Company Name: Collegium Pharmaceutical Inc.
Stock Symbol: COLL
Market: NASDAQ
Website: collegiumpharma.com

Menu

COLL COLL Quote COLL Short COLL News COLL Articles COLL Message Board
Get COLL Alerts

News, Short Squeeze, Breakout and More Instantly...

COLL - IXJ: Healthcare Dashboard For May

Pharmaceuticals and biotechnology are cheap relative to 11-year valuation averages. Life science tools and healthcare equipment are overvalued. IXJ: a global alternative to XLV. 10 stocks cheaper than their peers in May. For further details see: IXJ: Healthcare Dashb...

COLL - Collegium to Participate in H.C. Wainwright Global Investment Conference

STOUGHTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will present at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Mia...

COLL - Collegium Pharmaceutical, Inc. 2022 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Collegium Pharmaceutical, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Collegium Pharmaceutical, Inc. 2022 Q1 - Results - Earnings Call Presentation

COLL - Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2022 Results - Earnings Call Transcript

Collegium Pharmaceutical, Inc. (COLL) Q1 2022 Earnings Conference Call May 10, 2022 04:30 PM ET Company Participants Alex Dasalla - Head of IR & Corporate Communications Joe Ciaffoni - President and CEO Colleen Tupper - CFO Scott Dreyer - CCO Conference Call Participants David Amsellem - ...

COLL - Collegium Pharmaceutical GAAP EPS of -$0.39, revenue of $83.75M

Collegium Pharmaceutical press release (NASDAQ:COLL): Q1 GAAP EPS of -$0.39. Revenue of $83.75M (-4.5% Y/Y). 2022 Guidance: Total product revenues are expected in the range of $450.0 million to $465.0 million, up approximately 65% at the midpoint compared to net product revenue of $276.9...

COLL - Collegium Reports First Quarter 2022 Financial Results

- Generated Net Revenue of $83.8 Million - - Completed BDSI Acquisition; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million - - Resolved All Opioid-Industry Litigation - - Reaffirms 2022 Financial Guidance - - Conference Call Scheduled...

COLL - Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results

STOUGHTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2022 at 4:30 p.m. ET. The ...

COLL - IBB: Healthcare Dashboard For April

Pharmaceuticals and biotechnology still are attractive regarding value and quality. Other subsectors are overvalued by 15% to 42% relative to 11-year averages. Fast facts on IBB. 10 healthcare stocks cheaper than their peers in April. For further details see: IBB: He...

COLL - Shares of Collegium Pharmaceutical Inc. (COLL) Have Risen Above Previous 52-Week High

Collegium Pharmaceutical Inc. (NASDAQ:COLL) traded at a new 52-week high today of $29.65. Approximately 37.9 million shares have changed hands today, as compared to an average 30-day volume of 353,000 shares. Over the past year, Collegium Pharmaceutical Inc. has traded in a range of $7.3...

COLL - Collegium to Participate in Upcoming Needham Healthcare Conference

STOUGHTON, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will participate in the following investor conference: 21 st Annual Needham Vi...

Previous 10 Next 10